Закат
20:30
До Йом Кипур осталось
4 дня
05.07.2014
27 Нисан
Элула
banner
31.03.2015

Israeli firm Teva buying Auspex for $3.2 billion

Auspex's lead product candidate is aimed at treating symptoms associated with Huntington's disease.

Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.

Jerusalem-based Teva said Monday that it will pay $101 per share, marking a 47 percent premium to San Diego-based Auspex's closing stock price on Friday.

Auspex does not yet have a product on the market. Its lead product candidate is Austedo, which is aimed at treating involuntary movement associated with the genetic disorder Huntington's disease.

Source: Haaretz

1/6
4442

Igor Kolomoisky: I told Yatsenyuk he was putting himself at risk

On relations with the president, his administration and Prime Minister Arseny Yatsenyuk

4868

New High-Tech Collar Tracks The Health Of Your Pets

The PetPace collar uses non-invasive sensors to monitor data